Michelle Leigh Monje, MD, PHD
Neurology With Special Qualifications in Child Neurology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Monje’s office at (650) 497-8000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A93369 · Current
Licensed to practise in California · since 2005 · expires 2027-06-30 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · Phase I Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma · 2019 | Their institution | $1,244,081 |
| Novartis Pharmaceuticals Corporation · Phase I Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma · 2020 | Their institution | $73,200 |
| Incyte Corporation · Adam-10 Inhibition With Incb7839 for Pediatric High-Grade Gliomas To Target Microenvironmental Neuroligin-3 · 2022 | Their institution | $9,750 |
| PFIZER INC. · Phase I Study of Cdk 46 Inhibitor Pd0332991 Palbociclib Ibrance in Children With Recurrent Progressive Or Refractory Central Nervous System Tumors · 2019 | Their institution | $3,600 |
| Incyte Corporation · Adam-10 Inhibition With Incb7839 for Pediatric High-Grade Gliomas To Target Microenvironmental Neuroligin-3 · 2025 | Their institution | $2,000 |
| PFIZER INC. · Phase I Study of Cdk 46 Inhibitor Pd0332991 Palbociclib Ibrance in Children With Recurrent Progressive Or Refractory Central Nervous System Tumors · 2020 | Their institution | $1,000 |
Professional record
- NPI
- 1538385612
- Licence
- CA A93369California A93369: Current · expires 2027-06-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0402X (2084N0402X); Neurology (2084N0400X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2007-04-18
- NPI last updated
- 2023-11-10
- NPI record certified
- 2023-11-10
This is when the NPI record was last certified, not a medical board exam.